A small molecular marker for early diagnosis of lung cancer and its application in diagnosis

Abstract

The invention discloses a micromolecular marker for early diagnosis of lung cancer, and application thereof to diagnosis, and discloses a composition for the early diagnosis of the lung cancer. The composition at least comprises phosphatidylinositol (20 to 4 / 0 to 0), preferably, comprises the phosphatidylinositol (20 to 4 / 0 to 0), palmitoylethanolamine and citromalic acid. The phosphatidylinositol(20 to 4 / 0 to 0) is singly used for diagnosing AUC of lung cancer and non-lung cancer to be 0.858 and has moderate accuracy; and the palmitoylethanolamine, the phosphatidylinositol (20 to 4 / 0 to 0) and the citromalic acid are jointly used for diagnosing the AUC of lung cancer and non-lung cancer to be 0.965 and has relatively high accuracy, and the sensitivity and the specificity at the optimal diagnosis clinical value are both 0.9 or above. Through verification in an independent sample set, the accuracy degree of the serum palmitoylethanolamine, the phosphatidylinositol (20 to 4 / 0 to 0) andthe citromalic acid jointly used for diagnosing lung cancer and non-lung cancer is up to 92.2 percent, and the diagnosis value is high.

Description

technical field [0001] The invention belongs to the field of precise diagnosis, and relates to a small molecule marker for early diagnosis of lung cancer and its application in diagnosis. Background technique [0002] Lung cancer is a common malignant tumor. Its morbidity and mortality rank first among all kinds of malignant tumors, and it continues to rise. Because lung cancer is sometimes difficult to distinguish from benign lung diseases, it is easy to cause patients to miss the best treatment period and delay treatment. The gold standard for the diagnosis of lung cancer is pathological examination. This method has high specificity, but it is invasive and difficult for patients to accept. Moreover, it is difficult to obtain materials, resulting in low sensitivity, and it is more difficult to detect asymptomatic or X-ray recessive lung cancer. . Imaging examination is currently the main means of diagnosis of lung cancer. It can observe the location of the lesion by chang...

AI Technical Summary

Problems solved by technology

Because lung cancer is sometimes difficult to distinguish from benign lung diseases, it is easy to cause patients to miss the best treatment period and delay treatment

The gold standard for the diagnosis of lung cancer is pathological examination. This method has high specificity, but it is invasive and difficult for patients to accept. Moreover, it is difficult to obtain materials, resulting in low sensitivity, and it is more difficult to detect asymptomatic or X-ray recessive lung cancer.

Imaging examination is currently the main means of diagnosis of lung cancer. It can observe the location of the lesion by changing the body position, and clarify the stage of lung cancer. Early Diagnosis Requirements

[0003] The abnormality of serum tumor markers is often earlier than the abnormality of imaging. The detection is convenient, reproducible, and low in cost. For patients without clinically relevant symptoms, the abnormality of any marker may be suggestive, but in healthy people May also be elevated in patients with benign pulmonary disease

Images